<DOC>
	<DOCNO>NCT00353756</DOCNO>
	<brief_summary>The purpose study determine whether C326 , new inhibitor IL-6 , safe patient Crohn 's disease .</brief_summary>
	<brief_title>Phase 1 Study Safety Biological Effects C326 , Inhibitor IL-6 , Crohn â€™ Disease</brief_title>
	<detailed_description>Determination safety important goal first study C326 . Other goal study examine : - pharmacokinetics ( change serum concentration time ) , - biological activity ( change blood marker relecting activity Crohn 's Disease ) , - effect symptoms Crohn 's disease . Participants may receive either single several intravenous infusion C326 match placebo .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Adults 18 65 Stable , moderately active Crohn 's Disease Otherwise generally good health Variety concurrent medical condition Various concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>